Biogen (BIIB) Misses Q4 EPS by 23c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $225.36 --0%
EPS Growth %: -57.8%
Financial Fact:
Income from operations: 1.43B
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -57.8%
Financial Fact:
Income from operations: 1.43B
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $2.95, $0.23 worse than the analyst estimate of $3.18. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.47 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $15.00-$16.00, versus the consensus of $15.64.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance
- Worthington Industries (WOR) Tops Q1 EPS by 7c
- Oppenheimer Starts Collegium Pharmaceutical (COLL) at Outperform
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
